Validation of the Cukurova Score for ovarian cancer treatment decisions
Cukurova Score Validation Study in Prediction of Primary Cytoreduction in Advanced Ovarian Cancer
This study is testing a new scoring system to help doctors decide the best treatment options for patients with advanced ovarian cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 130 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | Female |
| Sponsor | Cukurova University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Adana) |
| Trial ID | NCT06378905 on ClinicalTrials.gov |
What this trial studies
This observational study aims to validate the Cukurova score, which prioritizes surgical procedures for patients with advanced-stage epithelial ovarian cancer based on radiological imaging and clinical performance rather than solely on tumor burden. The study will include patients who are suspected to have advanced ovarian cancer and have been pathologically confirmed to have Stage III-IV disease. By assessing the effectiveness of the Cukurova score, the study seeks to improve decision-making regarding primary cytoreductive surgery and neoadjuvant chemotherapy. The ultimate goal is to enhance surgical outcomes and patient management in advanced ovarian cancer cases.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and over with pathologically confirmed Stage III-IV epithelial ovarian cancer.
Not a fit: Patients with early-stage (Stage I-II) or non-epithelial ovarian cancers will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved surgical outcomes and tailored treatment strategies for patients with advanced epithelial ovarian cancer.
How similar studies have performed: While there have been various scoring systems developed for surgical decision-making in ovarian cancer, the Cukurova score represents a novel approach that has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years old and over * Suspected advanced ovarian/fallopian tube/ primary peritoneal carcinomatosis on imaging * Pathologically confirmed Stage III-IV epithelial ovarian cancer/fallopian tube/ primary peritoneal carcinomatosis * Consent to participate in the study Exclusion Criteria: * Stage I-II epithelial ovarian/fallopian tube/peritoneal cancer * Nonepithelial Ovarian Cancer * Benign Ovarian tumors * Borderline Ovarian Tumors * Metastatic Ovarian Tumors * Rejecting to Participate in the Study * \<18 years old
Where this trial is running
Adana
- Cukurova University — Adana, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Ghanim Khatib, MD
- Email: ghanim.khatib@gmail.com
- Phone: +903223386060
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.